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Corticosteroids and endothelial dysfunction
Assessment of endothelial-mediated relaxation in situ is rapidly becoming the standard
gauge of individual susceptibility to future cardiovascular dysfunction (Hadi et al
2005).
In this issue of Vascular Health and Risk Management, Turner and colleagues
(2005), in a pilot investigation, have proposed the concept that endothelial dysfunction
in patients with systemic lupus erythematosus, but with no known cardiovascular
disease, is the result of exposure to corticosteroids. Even though the study by Turner
and colleagues (2005) has a small sample size and may not have the desired power to
conclusively indicate the relationship between endothelial dysfunction and
corticosteroids use, it is worth considering the possible basis for such an association.
An interesting angle of this hypothesis is the impact of corticosteroids on the
plasma glucose levels and insulin. The metabolic actions of corticoid steroid, namely
cortisol, are well recognized, and it is counted among the counter-regulatory stress
hormones. Infusion of hydrocortisone is believed to increase plasma glucose, free
fatty acid, and insulin concentrations, and is thus believed to increase metabolic rate
in healthy individuals (Brillon et al 1995). Moreover, despite an elevated insulin
concentration, hypercortisolemia results in a significantly higher plasma glucose
concentration (Nielsen et al 2003). In addition, during the infusion of glucose in
healthy subjects, the integrated glycemic response above baseline is higher in the
presence of hydrocortisone than saline infusion, which suggests that plasma glucose
level is less rigorously controlled and seems to remain elevated for a longer duration
in presence of the glucocorticoid (Nielsen et al 2003). Of interest, is that treatment
with prednisolone, which reportedly causes insulin resistance, hyperinsulinemia, and
hyperglucagonemia (Gravholt et al 2002), as well as infusion of hydrocortisone,
also seems to result in insulin resistance (Nielsen et al 2003).
There is now ample evidence in the literature that provides both an acute and a
chronic link between glucose and endothelial dysfunction in animals and humans
(Ceriello 2004; Triggle et al 2005). Some compelling early evidence was presented
by Kawano and colleagues (1999), which indicated that flow-mediated vasodilation
is decreased after glucose loading in normal subjects and patients with type 2 diabetes
mellitus, and it was suggested that suppression of endothelium-dependent vasodilation
was probably due to the production of oxygen-derived free radicals. Moreover, Title
et al (2000) reported that the acute transient decrease in flow-mediated dilation in
healthy subjects by oral glucose could be prevented by vitamins C and E. It has also
been reported that administration of (6R)-5,6,7,8-tetrahydrobiopterin, but not (6S)-
5,6,7,8-tetrahydrobiopterin, can reverse the transient glucose-induced endothelial
dysfunction in healthy individuals (Ihlemann et al 2003).
Among the mechanisms that have been postulated to explain endothelial
dysfunction during elevation of plasma glucose levels are glycosylation of the insulin
receptor substrate, which eventually leads to an impediment in the ability of protein
kinase B (Akt) to enhance endothelial nitric oxide (NO) synthase activity, which
then manifests as a lower amount of NO being produced by the endothelial cells.
Another proposed mechanism is that an elevation of oxidative stress due to
hyperglycemia results in reduced levels of tetrahydrobiopterin, which subsequentlyVascular Health and Risk Management 2005:1(4) 262
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leads to an uncoupling of NO synthase that acts to produce
superoxide rather than NO (Triggle et al 2005). Both the
former and the latter mechanisms can account for the
decrease in NO generation and reduced vasodilation.
Recently, experimental data from rabbits seem to suggest
that glucose levels observed in daily clinical practice can
induce endothelial dysfunction in both macro- and micro-
circulation (Gomes et al 2004). Collectively, the majority
of the evidence in the literature seems to support the concept
that a spike in plasma glucose levels and/or uncontrolled
high plasma glucose levels have detrimental effects on
vascular function and clearly seem to cause impairment in
endothelial-mediated vasorelaxation, resulting in endothelial
dysfunction over the long-term. It may not be a far fetched
hypothesis that the basis for endothelial dysfunction in
patients with lupus erythematosus treated with gluco-
corticoids is a lack of rigorous control of plasma glucose
levels due to insulin resistance caused by glucorticoid use.
It seems that stress-related endothelial dysfunction can be
prevented by blocking cortisol production with metyrapone
in subjects without coronary heart disease risk factors, thus
presenting a direct facilitative role for cortisol in endothelial
dysfunction (Broadley et al 2005). This can be linked to
significant changes in plasma glucose level, among other
things. It is clear that the paper by Turner and colleagues
(2005) is hypothesis generating and obviously a much larger
study is warranted. However, it is also worthwhile to
consider whether glucose has a role and is the link between
endothelial dysfunction and glucocorticoid use in this
population of patients.
Cortisol also has a permissive effect in enhancing
vasoactive actions of catecholamines through glucocorticoid
receptors, and has been suggested to have pathogenic role
in secondary hypertension. The role of cortisol in
hypertension is the subject of an elegant review by
Whitworth et al (2005), also in this issue of Vascular Health
and Risk Management. This review also reaches the
conclusion that cortisol may affect the cardiovascular tree
by having a negative impact on the vasodilator actions of
NO. This would agree with the concept that glucocorticoids
have a protagonist and pivotal role in aiding and perhaps
inducing endothelial dysfunction in patients with lupus
erythematosus that are treated with this class of compounds.
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